Beyond Helicobacter pylori: Prevalence, Coinfection, and Clinicopathologic Patterns of Non‐Helicobacter pylori Helicobacter (NHPH) in Human Gastric Biopsies Authors: Daniel Vizenblit, Maya Azrad, Munir Nashashibi, Halim Roshrosh, Yaakov Maman, Avi Peretz Published: 2026 ABSTRACT ABSTRACTBackgroundNon‐ Helicobacter pylori Helicobacter (NHPH) species are increasingly recognized as human gastric colonizers, yet their prevalence, species distribution, and clinical significance remain incompletely defined, particularly in patient cohorts in the Middle East.Materials and MethodsIn this retrospective study, 830 formalin‐fixed paraffin‐embedded gastric biopsy samples collected from patients undergoing esophagogastroduodenoscopy at Tzafon Medical Center, northern Israel, between 2022 and 2024 were subjected to species‐specific PCR for H. pylori and NHPH species. Clinical, demographic, histopathological, and endoscopic data were correlated with PCR‐defined infection status.Results H. pylori was detected in 643/830 (77.5%), whereas at least one NHPH species was detected in 179 samples (21.6%). H. bizzozeronii was the predominant NHPH species, identified in 167/830 samples (20.1%), while H. heilmannii , H. felis , and H. ailurogastricus were rare (< 1%), and H. suis and H. salomonis were not detected. Co‐infection with H. pylori was common (18.2%), and was detected in 23.5% of all H. pylori ‐positive samples and 84.4% of NHPH‐positive samples. NHPH prevalence was higher in females and demonstrated marked seasonality, peaking in autumn. Histopathological comparison showed a significant difference in foveolar hyperplasia rates across infection groups, with higher frequencies in NHPH‐only and PCR detected negative for all species samples than in H. pylori ‐positive groups. In contrast, clinical symptoms and endoscopic findings were broadly comparable across infection strata.ConclusionsThese findings provide the first large‐scale molecular characterization of gastric NHPH in Israel and show that NHPH, predominantly H. bizzozeronii , is relatively common in this population, is usually co‐detected with H. pylori , and is associated more strongly with distinct epidemiologic and histopathologic patterns than with a distinct clinical or endoscopic phenotype.Keywords: coinfection, gastric biopsy, Helicobacter bizzozeronii, Helicobacter pylori, non‐Helicobacter pylori Helicobacter (NHPH), polymerase chain reaction (PCR), prevalence Introduction Gastric diseases span a wide spectrum from mild chronic gastritis to peptic ulcer disease and gastric cancer [1, 2] and constitute a significant global burden on healthcare systems. Helicobacter pylori (H. pylori) is the most prevalent gastric bacterial pathogen, with approximately 50% of the world population estimated to be colonized. H. pylori infection is strongly associated with a broad spectrum of gastroduodenal diseases, including chronic gastritis, peptic ulcer disease, gastric adenocarcinoma and mucosa‐associated lymphoid tissue (MALT) lymphoma [3]. However, non–Helicobacter pylori Helicobacter (NHPH) species have also been shown to colonize the human stomach [4, 5, 6, 7] and have been identified in approximately 0.2%–6% of patients undergoing gastroscopy [8]. NHPH infection is often indistinguishable from H. pylori both clinically [9] and histologically, As a result, their prevalence and clinical significance are likely underestimated [6, 7, 9, 10, 11, 12]. Overall, data regarding the prevalence and clinical significance of NHPH species in human gastric disease remain scarce [10, 11, 13], and to date, no systematic studies have been conducted in Israel. To place the present study in context, we compiled a focused narrative summary of representative human studies on gastric non‐ H. pylori Helicobacter infection, including study populations, diagnostic approaches, species distribution, and reported clinicopathological associations (Table 1). Relevant studies published from 2013 to 2025 were identified through targeted searches of PubMed and Google Scholar using combinations of terms related to non‐ H. pylori Helicobacter species, gastric disease, prevalence, and coinfection. This table was intended as a narrative overview rather than a formal systematic review. NHPH species encompass a heterogeneous group of organisms whose pathogenicity in humans is not yet fully defined [4, 14]. While several reports and experimental models suggest that specific species, particularly H. suis , contribute to chronic gastritis, peptic ulcer disease, gastric MALT lymphoma, and possibly gastric carcinogenesis [5, 7, 14, 15, 16], other studies have failed to demonstrate a consistent association between NHPH infection and gastric cancer or advanced premalignant lesions [17, 18] (Table 1). Overall, current data are limited by small sample sizes, heterogeneous diagnostic methods, and frequent co‐infection or prior exposure to H. pylori . Consequently, the true oncogenic potential of NHPH species and their contribution to human gastric malignancies remain controversial, underscoring the need for well‐designed epidemiological and molecular studies in different populations [7, 10, 17]. The present study aimed to assess the prevalence of NHPH in patients with gastric disease in northern Israel. Using molecular detection methods, archived gastric biopsies initially classified by routine histopathology were re‐evaluated for the presence of H. pylori and NHPH species. In addition, molecular findings were correlated with histopathological features, endoscopic findings, and patient demographic and clinical data to better characterize the epidemiology and clinical relevance of NHPH infection. TABLE 1Summary of studies on human gastric NHPH infection.Study (author, year) and countryStudy populationCohort definition according to H. pylori testingMethod used to assess H. pylori status H. pylori status of cohortNHPH detection methodNHPH species detection and prevalencePrevalence of co‐infection (NHPH+ H. pylori )Associated disease(s) and main finding(s)Blaecher et al. 2013 (UK) N = 316 60 patients with IP and 256 endoscopy controls H. pylori –positive and negative casesCulture + additional PCR for negative cultures IP group: 28/60 (47%) H. pylori positive Control group: 42/256 (16%) H. pylori positive Species‐specific real‐time PCR for H. suis with confirmation by nucleotide sequencing and MLST H. suis ; total‐ 18/316 (5.7%): IP patients: 16/60 (27%). Controls: 2/256 (0.8%) IP patients: 3/60 (5%)IPLiu et al., 2015 (China) N = 1517 adults with gastric disease and RUT–positive gastric biopsiesRUT–positive cases H. pylori culture and species‐specific PCR; sequencing confirmation1499/1517 (98.8%) confirmed as H. pylori –positiveSpecies‐specific PCR with sequencing confirmation Total NHPH; 178/1499 (11.9%): H. suis : 6.94%; H. salomonis : 2.54%; H. felis : 2.2%; H. bizzozeronii : 0.13%; H. heilmannii s.s.: 0.07%; multiple‐species co‐infections observed 178/1499 (11.9%)Chronic gastritis; peptic ulcer disease (co‐infected patients)Øverby et al. 2017 (Japan) Adults undergoing upper GI endoscopy for gastric disease (N = 280) Controls (n = 64): symptomatic patients without endoscopic gastric disease H. pylori –positive and negative casesSpecies‐specific PCR; IHC 184/280 (65.7%) gastric disease patients tested positive for H. pylori Control group: 47/64 (73.4%) Species‐specific PCR; IHC Total NHPH; 17/280 (6.1%): H. suis 2.5%; H. heilmannii s.s. 0.4%; other spp. 1.4% (identification only for 12 samples) Control group: 0/64 (0%) 12/280 (4.2%)Gastric MALT lymphoma; duodenal ulcer (co‐infected patients)Bahadori et al. 2018 (Turkey) N = 110 children with gastric complaints undergoing gastroscopy H. pylori –positive and negative casesPCR, rapid urease test (CLOtest) and histopathology34/110 (30.9%) children tested positive for H. pylori Species‐specific PCR with sequencing confirmation Total NHPH; 3/110 (2.7%): H. suis : 1.8%; H. heilmannii /H. ailurogastricus: 0.9% 1/110 (0.9%) H. suis and H. pylori Chronic gastritis; nodular gastritis; gastric ulceration (mainly in co‐infected patients)Tarhane et al., 2019 (Turkey) N = 195 patients with abdominal pain undergoing endoscopy and testing H. pylori –positive and negative casesHistopathology and PCR87/195 (44.61%) were positive for H. pylori PCR and histologyNone detectedNone detectedAbdominal painAugustin et al. 2019 (UK) N = 60 patients with Parkinson's disease undergoing gastroduodenal endoscopy H. pylori –positive and negative cases (19‐post‐eradication+ 41‐ no‐treatment exposure) UBT, culture, and PCR17/60 (28.3%) tested positive for H. pylori (all from the no‐treatment exposure group)Species‐specific qPCR with sequencing confirmation H. suis 19/60 (31.7%): no other NHPH detected3/19 (15.7%) with H. suis and H. pylori Chronic gastritis (histology sparse/patchy) H. suis positivity associated with increased mortality Mohammadi et al. 2019 (Iran) N = 190 adults undergoing upper GI endoscopy for gastroduodenal complaints H. pylori –positive and negative casesPCR for H. pylori 120/190 (63%) tested positive for H. pylori PCR (species‐specific primers) Total NHPH; 41/190 (21.6%): H. heilmannii : 20%; H. bizzozeronii : 1.6% None detectedGastritis; duodenal ulcer; gastric cancerShafaie et al. 2020 (Iran) N = 428 dyspeptic patients undergoing upper GI endoscopyMixed cohort; H. pylori –posit H. pylori –positive and negative casesRUT and histology368/428 (86%) tested positive for H. pylori PCR; NHPH screened only in H. pylori –negative subgroup Total NHPH; 60/428 (14%): H. salomonis : 4.7%; H. heilmannii : 3%; H. felis : 2.3%; H. suis : 2.3%; H. bizzozeronii : 1.6% None detectedGastritis; duodenal ulcer; gastric ulcerNakamura et al. 2020 (Japan) N = 265 patients with gastric diseases defined as H. pylori –negative by routine tests (RUT + histology) H. pylori –negative cohort; post‐eradication‐ with negative UBT(29); Non‐ H. pylori Eradication history (236)PCR used to exclude H. pylori ‐positive cases31/296 (10.5%) initially Hp‐negative tested positive for H. pylori by PCR and were excludedPCR and IHC (subset) Total NHPH; 56/296 (18.9%): Non‐eradication history group; 49/236 (20.8%): H. suis : 8.5%; H. heilmannii s.s./H. ailurogastricus: 3%; unidentified: 9.3%. Post‐eradication group; 3/29 (10.3%): H. heilmannii s.s./H. ailurogastricus: 3.4%; unidentified: 6.9%. Positive for H. pylori (excluded from the final analysis); 4/31 (12.9%): H. suis: 6.5%; H. heilmannii s.s./H. ailurogastricus: 3.2%; unidentified: 3.2% 4/296 (1.35%); excluded from the final analysisChronic gastritis; nodular gastritis; MALT lymphoma; ulcer diseaseTsukadaira et al. 2021 (Japan) N = 3847: patients undergoing upper GI endoscopy; NHPH‐positive cases identified among biopsy samples H. pylori –positive and negative cases Supplementary tests were conducted for 50 NHPH cases only: –anti‐ H. pylori antibody (serology): 50 tested–UBT: 30 tested–Stool antigen: 33 tested–RUT: 24 tested All tested cases were defined as negative for H. pylori PCR Total NHPH; 50/3847 (1.3%): H. suis : 0.7%; H. heilmannii /H. ailurogastricus: 0.05; remaining NHPH not further specified None detectedGastritis; peptic ulcer diseaseTakigawa et al. 2021 (Japan) N = 182 patients with localized gastric MALT lymphoma and receiving eradication therapy as first‐line treatment Defined cohort group based on H. pylori testing Patients with API2‐MALT1 were excluded after the basic selection Anti– H. pylori IgG serology; successful eradication confirmed by urea breath test H. pylori ‐positive: 148/182 (81.3%) H. pylori ‐negative: 34/182 (18.7%) PCR Total NHPH PCR subanalysis; 19/58 (32.8%): H. pylori ‐negative cases (16/29, 55%): H. suis :17.2%; H. bizzozeronii : 27.6%; H. suis + H. bizzozeronii : 10.3%. H. pylori ‐positive cases (3/29, 10.3%): H. bizzozeronii : 6.9%; H. suis + H. bizzozeronii :3.4% 3/29 (10%)Gastric MALT lymphomaMatos et al. 2022 (Portugal) N = 80 patients with gastric symptoms undergoing endoscopy H. pylori –positive and negative casesUBT, histology, and prior treatment historyNot reportedPCR Total NHPH; 19/80 (23.7%) H. suis : 8.75%; H. felis : 5%; H. salomonis : 3.75%; H. bizzozeronii : 3.75%; H. heilmannii : 2.5% Not reportedGastritisYasuda et al. 2022 (Korea) N = 281 patients with early gastric cancer treated by endoscopic submucosal dissection H. pylori –positive and negative cases; no prior H. pylori eradicationSerum H. pylori IgG; PCR; rapid urease test (RUT); pepsinogen (ABCD method) The rate of H. pylori positivity based on blood‐antibody (IgG) testing was 183/281 (65.1%) Among NHPH‐positive cases: one H. pylori PCR–positive, one H. pylori IgG–positive, one H. pylori –negative by PCR and serology Real‐time PCR with sequencing confirmation; immunohistochemistry for H. suis Total NHPH; 3/281 (1.1%): Helicobacter suis (IHC‐confirmation in 2 cases); one NHPH case not species‐identified2/3 (66.6%)Early gastric cancer (intestinal‐type adenocarcinoma, antrum)Taillieu et al. 2023 (Belgium) Retrospective n = 464; prospective n = 65; Controls n = 38 adults with H. pylori ‐negative gastric disease; asymptomatic gastric bypass patients served as controls H. pylori –negative cohortsHistology and IHC and/or serology for initial H. pylori‐negative samples selection; H. pylori –specific PCR with sequencing for confirmationLow‐level H. pylori DNA detected by PCR in 11.6% of retrospective patients and 1.5% of prospective patientsPCR on gastric biopsies/cytobrushes with confirmatory Sanger sequencing Retrospective: 135/464 (29.1%); H. bizzozeronii : 10.13%; H. felis : 8.84%; H. suis : 4.74%; H. salomonis : 0.86%; H. heilmannii s.s.: 0.22%; mixed infections: 3.66%. Unspecified dog/cat‐associated NHPH: 0.65% Prospective: 18/65 (27.7%); H. bizzozeronii : 10.77%; H. felis : 9.23%; H. salomonis : 4.62%; mixed infections: 1.54% Unspecified dog/cat‐associated NHPH: 1.54% Retrospective: 22/464 (4.7%)Chronic gastritis (including non‐atrophic, atrophic, intestinal metaplasia); peptic ulcer disease; gastric MALT lymphomaAbuduwaili et al. 2023 (Japan) N = 73 patients with early gastric cancer treated by endoscopic submucosal dissectionDefined cohort groups based on H. pylori testingCombination of endoscopy (Kyoto classification), anti– H. pylori IgG serology, UBT (in discrepant cases), and histology H. pylori current infection (n = 21), H. pylori previous infection (n = 37), H. pylori naïve (n = 15)PCRNot individually quantified by species; overall NHPH positivity 9/73 (12%) H. pylori current: 19% H. pylori previous: 11% H. pylori naïve: 7% Early gastric cancer; background chronic gastritisMatsui et al. 2023 (Japan) N = 101 adults undergoing upper GI endoscopy for gastric disorders; healthy stomachs excludedDefined cohort groups based on H. pylori testingCulture and PCR from gastric biopsy specimens; colony PCR targeting 23S rRNA H. suis infection (n = 20), H. pylori infection (n = 17), post– H. pylori eradication (n = 20), non‐infected (n = 44)Culture, PCR, serology (whole‐cell ELISA) H. suis ; 20/101 (19.8%)None detectedGastritis; gastric MALT lymphoma; peptic ulcer; autoimmune (metaplastic atrophic) gastritisChang et al. 2024 (USA) N = 38 children with H. heilmannii ‐associated gastritis undergoing upper GI endoscopy H. pylori –negative cohortHistology with H. pylori –IHCNot reported.Histology identification (morphology on H&E); immunohistochemistry H. heilmannii sensu lato; 38/38 (100%) (not further subtyped; molecular methods not routinely performed)None detectedChronic gastritis (all cases); nodular gastritis; gastric ulcer (rare)Okamura et al. 2024 (Japan) N = 2087 adults undergoing upper GI endoscopy; retrospective comparison of NHPH gastritis vs. mild atrophic H. pylori gastritisDefined groups based on Helicobacter testingHistology with anti– H. pylori IHC and/or Giemsa stainingAfter exclusion: NHPH‐infected (n = 9); H. pylori ‐infected with mild atrophy(n = 134)Histology suggesting NHPH followed by PCR H. suis 9/2087 (0.4%)None detectedChronic gastritis; nodular gastritis; gastric MALT lymphomaCortez Nunes et al. 2025 (Portugal) N = 54: Adult patients undergoing upper GI endoscopy H. pylori –positive and negative cases.Histology (Modified Giemsa staining) + PCR Giemsa staining: 23/54 (42.6%) tested positive for H. pylori. PCR: 18/54 (33.3%) tested positive for H. pylori PCR. H. bizzozeroni; 14/54 (25.9%)12/54 (22.2%)Symptoms in 51.9%; endoscopic gastritis in 66.7%, histological gastritis in 88.9%; mixed infections in 22.2%Tokunaga et al. 2025 (Japan) N = 673 prospective multicenter cohort of patients undergoing upper GI endoscopy H. pylori –positive and negative casesCombination: UBT, serology, RUT, histology, endoscopic findings H. pylori –negative: 393/673 (58.4%), post‐eradication: 256/673 (38%), and H. pylori –positive: 24/673 (3.6%) NHPH validation by PCR revealed that 4 samples initially deemed H. pylori ‐positive are actually NHPH‐positive and H. pylori ‐negative, necessitating reclassification of the groups PCR (gastric juice); ELISA for H. suis Total NHPH; 20/673 (3%): H. suis : 2.1%; non– H. suis NHPH: 0.9%. None detectedGastritis; gastric MALT lymphomaYi Fan Chen et al. 2025 (USA) N = 1115 routine gastric biopsies submitted for drug susceptibility genotyping at a large academic medical center H. pylori –positive and negative casesNGS and histology NGS confirmed H. pylori positive: 1094/1115 (98.1%) H. pylori negative: 14/1115 (1.2%) NGS and histology Total NHPH; 15/1115 (1.35%): H. heilmannii : 0.81%; H. felis : 0.27%; H. bizzozeronii : 0.27% 8/15 (53.3%)GastritisAbbreviations: ABCD method, serum pepsinogen/anti‐ H. pylori antibody‐based ABCD classification; API2‐MALT1, apoptosis inhibitor 2‐mucosa‐associated lymphoid tissue lymphoma translocation protein 1; CLOtest, Campylobacter‐like organism test; ELISA, enzyme‐linked immunosorbent assay; H&E, hematoxylin and eosin; H. ailurogastricus, Helicobacter ailurogastricus; H. bizzozeronii , Helicobacter bizzozeronii ; H. felis , Helicobacter felis ; H. heilmannii s.s., Helicobacter heilmannii sensu stricto; H. pylori , Helicobacter pylori ; H. salomonis , Helicobacter salomonis ; H. suis , Helicobacter suis ; IgG, immunoglobulin G; IHC, immunohistochemistry; IP, idiopathic parkinsonism; MALT, mucosa‐associated lymphoid tissue; MLST, multilocus sequence typing; NGS, next‐generation sequencing; NHPH, non‐ H. pylori Helicobacter; PCR, polymerase chain reaction; qPCR, quantitative polymerase chain reaction; RUT, rapid urease test; spp., species; UBT, urea breath test. Summary of studies on human gastric NHPH infection. N = 316 60 patients with IP and 256 endoscopy controls IP group: 28/60 (47%) H. pylori positive Control group: 42/256 (16%) H. pylori positive H. suis ; total‐ 18/316 (5.7%): IP patients: 16/60 (27%). Controls: 2/256 (0.8%) Total NHPH; 178/1499 (11.9%): H. suis : 6.94%; H. salomonis : 2.54%; H. felis : 2.2%; H. bizzozeronii : 0.13%; H. heilmannii s.s.: 0.07%; multiple‐species co‐infections observed Adults undergoing upper GI endoscopy for gastric disease (N = 280) Controls (n = 64): symptomatic patients without endoscopic gastric disease 184/280 (65.7%) gastric disease patients tested positive for H. pylori Control group: 47/64 (73.4%) Total NHPH; 17/280 (6.1%): H. suis 2.5%; H. heilmannii s.s. 0.4%; other spp. 1.4% (identification only for 12 samples) Control group: 0/64 (0%) Total NHPH; 3/110 (2.7%): H. suis : 1.8%; H. heilmannii /H. ailurogastricus: 0.9% H. pylori –positive and negative cases (19‐post‐eradication+ 41‐ no‐treatment exposure) Chronic gastritis (histology sparse/patchy) H. suis positivity associated with increased mortality Total NHPH; 41/190 (21.6%): H. heilmannii : 20%; H. bizzozeronii : 1.6% PCR; NHPH screened only in H. pylori –negative subgroup Total NHPH; 60/428 (14%): H. salomonis : 4.7%; H. heilmannii : 3%; H. felis : 2.3%; H. suis : 2.3%; H. bizzozeronii : 1.6% Total NHPH; 56/296 (18.9%): Non‐eradication history group; 49/236 (20.8%): H. suis : 8.5%; H. heilmannii s.s./H. ailurogastricus: 3%; unidentified: 9.3%. Post‐eradication group; 3/29 (10.3%): H. heilmannii s.s./H. ailurogastricus: 3.4%; unidentified: 6.9%. Positive for H. pylori (excluded from the final analysis); 4/31 (12.9%): H. suis: 6.5%; H. heilmannii s.s./H. ailurogastricus: 3.2%; unidentified: 3.2% Supplementary tests were conducted for 50 NHPH cases only: –anti‐ H. pylori antibody (serology): 50 tested–UBT: 30 tested–Stool antigen: 33 tested–RUT: 24 tested –anti‐ H. pylori antibody (serology): 50 tested anti‐ H. pylori antibody (serology): 50 tested –UBT: 30 tested UBT: 30 tested –Stool antigen: 33 tested Stool antigen: 33 tested –RUT: 24 tested RUT: 24 tested Total NHPH; 50/3847 (1.3%): H. suis : 0.7%; H. heilmannii /H. ailurogastricus: 0.05; remaining NHPH not further specified Defined cohort group based on H. pylori testing Patients with API2‐MALT1 were excluded after the basic selection H. pylori ‐positive: 148/182 (81.3%) H. pylori ‐negative: 34/182 (18.7%) Total NHPH PCR subanalysis; 19/58 (32.8%): H. pylori ‐negative cases (16/29, 55%): H. suis :17.2%; H. bizzozeronii : 27.6%; H. suis + H. bizzozeronii : 10.3%. H. pylori ‐positive cases (3/29, 10.3%): H. bizzozeronii : 6.9%; H. suis + H. bizzozeronii :3.4% Total NHPH; 19/80 (23.7%) H. suis : 8.75%; H. felis : 5%; H. salomonis : 3.75%; H. bizzozeronii : 3.75%; H. heilmannii : 2.5% The rate of H. pylori positivity based on blood‐antibody (IgG) testing was 183/281 (65.1%) Among NHPH‐positive cases: one H. pylori PCR–positive, one H. pylori IgG–positive, one H. pylori –negative by PCR and serology Retrospective n = 464; prospective n = 65; Controls n = 38 adults with H. pylori ‐negative gastric disease; asymptomatic gastric bypass patients served as controls Retrospective: 135/464 (29.1%); H. bizzozeronii : 10.13%; H. felis : 8.84%; H. suis : 4.74%; H. salomonis : 0.86%; H. heilmannii s.s.: 0.22%; mixed infections: 3.66%. Unspecified dog/cat‐associated NHPH: 0.65% Prospective: 18/65 (27.7%); H. bizzozeronii : 10.77%; H. felis : 9.23%; H. salomonis : 4.62%; mixed infections: 1.54% Unspecified dog/cat‐associated NHPH: 1.54% H. pylori current: 19% H. pylori previous: 11% H. pylori naïve: 7% Giemsa staining: 23/54 (42.6%) tested positive for H. pylori. PCR: 18/54 (33.3%) tested positive for H. pylori H. pylori –negative: 393/673 (58.4%), post‐eradication: 256/673 (38%), and H. pylori –positive: 24/673 (3.6%) NHPH validation by PCR revealed that 4 samples initially deemed H. pylori ‐positive are actually NHPH‐positive and H. pylori ‐negative, necessitating reclassification of the groups Total NHPH; 20/673 (3%): H. suis : 2.1%; non– H. suis NHPH: 0.9%. NGS confirmed H. pylori positive: 1094/1115 (98.1%) H. pylori negative: 14/1115 (1.2%) Total NHPH; 15/1115 (1.35%): H. heilmannii : 0.81%; H. felis : 0.27%; H. bizzozeronii : 0.27% Abbreviations: ABCD method, serum pepsinogen/anti‐ H. pylori antibody‐based ABCD classification; API2‐MALT1, apoptosis inhibitor 2‐mucosa‐associated lymphoid tissue lymphoma translocation protein 1; CLOtest, Campylobacter‐like organism test; ELISA, enzyme‐linked immunosorbent assay; H&E, hematoxylin and eosin; H. ailurogastricus, Helicobacter ailurogastricus; H. bizzozeronii , Helicobacter bizzozeronii ; H. felis , Helicobacter felis ; H. heilmannii s.s., Helicobacter heilmannii sensu stricto; H. pylori , Helicobacter pylori ; H. salomonis , Helicobacter salomonis ; H. suis , Helicobacter suis ; IgG, immunoglobulin G; IHC, immunohistochemistry; IP, idiopathic parkinsonism; MALT, mucosa‐associated lymphoid tissue; MLST, multilocus sequence typing; NGS, next‐generation sequencing; NHPH, non‐ H. pylori Helicobacter; PCR, polymerase chain reaction; qPCR, quantitative polymerase chain reaction; RUT, rapid urease test; spp., species; UBT, urea breath test. Materials and Methods Gastric Biopsy Clinical Specimens Study Set and Data Collection The study set included a random selection of 830 formalin‐fixed paraffin‐embedded (FFPE) gastric biopsy samples collected from different patients experiencing gastric complaints who underwent esophagogastroduodenoscopy (EGD) at Tzafon Medical Center between 2022 and 2024. All associated clinical data were anonymized. The study was approved by the Ethical Approval Committee of the Tzafon Medical Center (POR‐0067‐22), which waived the need for patient consent. The following demographic and clinical data were collected from patient records: age, gender, nationality, place of residence, biopsy site, pathological changes, gastritis‐related findings and gastroscopic lesion detection. Patient signs, symptoms, and gastroscopy reasons were also collected. Determination of NHPH Prevalence by PCR The gastric biopsy specimens were formalin‐fixed and paraffin‐embedded prior to sectioning. FFPE tissue blocks were sectioned using a microtome to a thickness of 20 μm, and the sections were preserved in nuclease‐free tubes for subsequent DNA extraction and molecular analysis. The MagCore Genomic DNA FFPE One‐Step Kit and MagCore Automated Extraction instruments were used to extract total DNA from FFPE sectioned tissues. For positive controls, genomic DNA was purchased from the American Type Culture Collection (USA) and the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), and was also extracted from Helicobacter ATCC 43504 strain using the Promega Wizard Genomic DNA Purification Kit (Promega, Madison, USA), as described below. The extracted DNA was preserved at −80°C, until further use. Helicobacter Species‐Specific PCR Assay PCR was performed using the previously described specific primers and running conditions [9, 17, 19, 20, 21] (Table A1). Each 20 μL reaction mixture was comprised of 80 ng purified genomic DNA, 10 μL Hy‐Taqman master mix (Hy Laboratories Ltd., Rehovot, Israel), and 1 μL of each gene‐specific primer (0.5 μM). The remaining volume was PCR‐grade water. Bacterial DNA of the above‐mentioned control strains served as a positive control, and PCR‐grade water as a negative control. The amplified products were separated by 3% agarose gel electrophoresis. Images were acquired using a UV Imaging System (Bio‐Rad, California, USA). Statistical Analysis Statistical analyses were performed using R software. Categorical variables were summarized as counts and percentages and compared between groups using the chi‐squared test or Fisher's exact test, as appropriate. Fisher's exact test was used when expected cell counts were small. Prevalence estimates were presented with 95% confidence intervals calculated using the Wilson method. Analyses were conducted using available PCR data only. A two‐sided p‐value of ≤ 0.05 was considered statistically significant. Large Language Models ChatGPT 4o was utilized to enhance English writing and ensure fluency and grammatical correctness. Results Patient Characteristics, Demographic Features and Seasonal Infection Patterns A total of 830 patients were included [380 males (45.8%), 450 females (54.2%)], of which 214 were aged < 18 years (25.8%), 161 aged 18–40 years (19.4%), 218 aged 41–60 years (26.3), and 237 aged ≥ 61 years (28.6) (Table 2). Patients were predominantly Jewish (655/830, 78.9%), a smaller subset were Arab (166/830, 20%) and a small minority were of other or unknown nationality (9/830, 1.1%). Residence type was primarily city (478/830, 57.6%), while the remaining patients lived in villages (244/830, 29.4%) or local councils (108/830, 13%) (Table 2). TABLE 2Patient characteristics, sampling site, and sampling time patterns (N = 830).Characteristic n (%)a,b GenderMale380 (45.8)Female450 (54.2)Age group (years)< 18214 (25.8)18–40161 (19.4)41–60218 (26.3)≥ 61237 (28.6)Nationality/sectorJewish655 (78.9)Arab166 (20.0)Other/unknown9 (1.1)Residence typeCity478 (57.6)Village244 (29.4)Local council108 (13.0)Biopsy siteAntrum492 (59.3)Corpus167 (20.1)Both antrum and corpus165 (19.9)Other gastric sites6 (0.7)Season of samplingAutumn229 (27.6)Spring224 (27.0)Summer196 (23.6)Winter181 (21.8) a Percentages were calculated within each subgroup. b Analyses were conducted on available PCR data only. Patient characteristics, sampling site, and sampling time patterns (N = 830). Percentages were calculated within each subgroup. Analyses were conducted on available PCR data only. Biopsies were obtained from the antrum in 492/830 (59.3%) cases, the corpus in 167/830 (20.1%), and from both antrum and corpus in 165/830 (19.9%) cases. In six cases (0.7%), samples were collected from other gastric sites. Samples were collected throughout the year, with similar distribution across seasons (autumn: 229/830 (27.6%); spring: 224/830 (27.0%); summer: 196/830 (23.6%); winter: 181/830 (21.8%)). H. pylori was detected by PCR in 643/830 (77.5%) samples, with similar prevalence in males (294/380, 77.4%) and females (349/450, 77.6%). At least one NHPH species was detected in 179/830 (21.6%), and was more frequent in females (110/450, 24.4%) than in males (69/380, 18.2%; p = 0.0282) (Table A2). NHPH prevalence was highest among the < 18‐year group (58/214, 27.1%), but did not differ significantly across age strata (Table A3). A non‐significant trend toward higher NHPH prevalence was observed in local councils (27.8%) and villages (23.8%) compared with cities (19.0%; p = 0.0833) (Table A5). NHPH prevalence varied significantly by season, peaking in autumn (31.9%) (p < 0.0001) (Table A7). Patient characteristics, sampling site and sampling time patterns are summarized in Table 2. Prevalence and Species Distribution of Non‐ H. pylori Helicobacter The most prevalent NHPH species was H. bizzozeronii , which was detected in 167/830 samples (20.1%). Other NHPH species, detected at substantially lower frequencies, included H. heilmannii (7/830, 0.8%), H. felis (6/830, 0.7%) and H. ailurogastricus (3/830, 0.4%) (Figure 1). H. suis or H. salomonis were not detected in any samples. Distribution of NHPH species across demographic and sampling characteristics is summarized in Tables A2, A3, A4, A5, A6, A7. Non‐Helicobacter pylori Helicobacter species distribution in North Israel. Non‐ Helicobacter pylori Helicobacter (NHPH) species were detected by PCR followed by gel electrophoresis, as outlined in the Section 2. (A) NHPH prevalence across the 830 samples screened. (B) The prevalence of specific NHPH species among the 179 NHPH‐positive samples. H. bizzozeronii prevalence was higher in females than in males (104/450, 23.1% vs. 63/380, 16.6%; p = 0.0193) and showed marked seasonality, peaking in autumn (68/229, 29.7%) compared with spring (35/224, 15.6%), summer (28/196, 14.3%), and winter (36/181, 19.9%; p = 0.0002) (Table A7). Across age strata, H. bizzozeronii was most commonly identified in patients < 18 years (56/214, 26.2%) but did not differ significantly overall across age groups (p = 0.0730). Differences by residence type (city 85/478, 17.8%; village 54/244, 22.1%; local council 28/108, 25.9%; p = 0.0948) and biopsy site (antrum 93/492, 18.9%; corpus 39/167, 23.4%; antrum plus corpus 34/165, 20.6%; p = 0.2293) were not statistically significant (Tables A5 and A6). NHPH + H. pylori Co‐Infection Patterns A total of 151 of the 643 H. pylori ‐positive samples (23.5%) tested positive for co‐infection with at least one NHPH species, while the majority of NHPH‐positive samples (151/179, 84.4%) were also positive for H. pylori . Among NHPH‐positive samples, H. bizzozeronii was detected in 140/151 (92.7%) co‐infected samples and 27/28 (96.4%) NHPH‐only samples, while H. heilmannii (7/151, 4.6%) and H. felis (6/151, 4.0%) were exclusively observed in the co‐infection group. H. ailurogastricus was rare in both strata (2/151, 1.3% vs. 1/28, 3.6%). Co‐detection of two NHPH species was uncommon and only occurred among samples co‐infected with H. pylori and NHPH species (4/151, 2.6%), whereas all NHPH‐only samples harbored a single NHPH species (28/28, 100.0%) (Table 3). TABLE 3Distribution of NHPH species by H. pylori co‐infection status.Category/organismNHPH+ H. pylori + (N = 151), n (%) a , b NHPH+ H. pylori − (N = 28), n (%) a , b Total NHPH+ (N = 179), n (%) a , b Any NHPH c 151, 100.0%28, 100.0%179, 100.0%Single NHPH species147, 97.4%28, 100.0%175, 97.8%≥ 2 NHPH species4, 2.6%0, 0.0%4, 2.2% H. bizzozeronii 140, 92.7%27, 96.4%167, 93.3% H. heilmannii 7, 4.6%0, 0.0%7, 3.9% H. felis 6, 4.0%0, 0.0%6, 3.4% H. ailurogastricus 2, 1.3%1, 3.6%3, 1.7% H. suis 0, 0.0%0, 0.0%0, 0.0% H. salomonis 0, 0.0%0, 0.0%0, 0.0% H. bizzozeronii + H. heilmannii 3, 2.0%0, 0.0%3, 1.7% H. bizzozeronii + H. felis 1, 0.7%0, 0.0%1, 0.6%Abbreviation: NHPH, non‐ H. pylori Helicobacter. a Percentages were calculated within each NHPH‐positive subgroup. b Species counts are not mutually exclusive due to the co‐detection of more than one NHPH species in individual samples. c “Any NHPH” indicates detection of at least one non‐ H. pylori Helicobacter species; totals may exceed due to co‐detection of multiple NHPH species in individual samples. Distribution of NHPH species by H. pylori co‐infection status. Abbreviation: NHPH, non‐ H. pylori Helicobacter. Percentages were calculated within each NHPH‐positive subgroup. Species counts are not mutually exclusive due to the co‐detection of more than one NHPH species in individual samples. “Any NHPH” indicates detection of at least one non‐ H. pylori Helicobacter species; totals may exceed due to co‐detection of multiple NHPH species in individual samples. Histopathological Characteristics by Helicobacter Infection Status To assess whether PCR‐defined infection status translated into distinct tissue‐level pathology, histopathological features were compared across four groups: co‐infection ( H. pylori + and NHPH+), H. pylori only ( H. pylori + and NHPH−), NHPH only ( H. pylori − and NHPH+), and PCR‐negative ( H. pylori − and NHPH−). Foveolar hyperplasia was observed in a significantly higher proportion of NHPH‐only samples (8/28, 28.6%; p < 0.0001), as compared to co‐infected (15/151 (9.9%)), H. pylori ‐only (47/492 (9.6%)) and PCR‐negative (38/159, 23.9%) samples. Both dysplasia (0/28, 0/151, 0/492, and 1/159 (0.6%), p = 0.2381), and gastric cancer cases (0/28 (0.0%), 1/151 (0.7%), 1/492 (0.2%), and 1/159 (0.6%), p = 0.7677) were rare, with no significant between‐group differences. In a species‐focused analysis restricted to H. bizzozeronii , the predominant NHPH, the same pattern was observed, with foveolar hyperplasia more frequent in H. bizzozeronii mono‐infection (8/27, 29.6%) and PCR‐negative (38/160, 23.8%) samples than in H. bizzozeronii ‐ H. pylori co‐infection (13/140, 9.3%) and in H. pylori only (49/503, 9.7%) samples (p < 0.0001). Endoscopic Findings by Helicobacter Infection Status Within the NHPH‐only group, gastritis‐related endoscopic findings were observed in 13/28 cases (46.4%) and consisted of diffuse redness (10 cases), nodularity (two cases), and enlarged folds (one case). No cases of endoscopic atrophy or suspected intestinal metaplasia were observed in the NHPH‐only group. Esophagitis (5/28, 17.9%) and duodenal involvement, including any duodenal peptic lesion (5/28, 17.9%), duodenitis (5/28, 17.9%) and duodenal erosions (4/28, 14.3%). Overall, there was no evidence that NHPH infection, either alone or in combination with H. pylori , was associated with an increased frequency of gastric or duodenal pathology compared with H. pylori mono‐infection. In fact, gastritis detection rates were similar in the co‐infection and H. pylori ‐only groups (87/151, 57.6% and 278/492, 56.5%, respectively) and lower in the NHPH‐only and PCR‐negative groups (13/28, 46.4% and 76/159, 47.8%, respectively); however, this difference was not statistically significant (p = 0.172). Duodenal findings were more common in the NHPH‐only group, including any duodenal peptic lesion (NHPH‐only: 5/28, 17.9%; co‐infection: 14/151, 9.3%; H. pylori only: 62/492, 12.6%; p = 0.3753) and duodenal erosions (NHPH‐only: 4/28, 14.3%; co‐infection: 11/151, 7.3%; H. pylori only: 49/492, 10.0%; p = 0.4788). In a species‐focused analysis restricted to H. bizzozeronii , spotty redness was more frequent in samples co‐infected with H. bizzozeronii and H. pylori compared with those with H. pylori mono‐infection (15/140, 10.7% vs. 23/503, 4.6%), but this difference did not reach statistical significance (p = 0.0597). Clinical Symptoms by Helicobacter Infection Status Within the NHPH‐only group, abdominal pain (15/28, 53.6%), followed by vomiting (3/28, 10.7%), GERD/heartburn (3/28, 10.7%), and iron deficiency anemia (2/28, 7.1%) were the most frequently reported clinical symptoms, while melena and weight loss were not reported at all (0/28, 0.0% each). Symptom rates were broadly comparable across the four infection groups, with abdominal pain remaining the predominant symptom (75/151, 49.7% in co‐infection; 276/492, 56.1% in H. pylori only; 15/28, 53.6% in NHPH only; and 82/159, 51.6% in PCR‐negative; p = 0.4954). Rates of vomiting (p = 0.7181), GERD/heartburn (p = 0.8398), weight loss (p = 0.6999), iron deficiency anemia (p = 0.3235), and melena (p = 0.4536) did not differ significantly by infection status (Tables A8 and A9). Similarly, in a species‐focused analysis restricted to H. bizzozeronii , symptom profiles showed no between‐group differences (Tables A8 and A9). Discussion In the study sample of 830 gastric biopsies, NHPH was detected in 21.6%. The most common species was H. bizzozeronii (20.1%), whereas H. heilmannii , H. felis and H. ailurogastricus were very rare and H. suis and H. salomonis were not detected. Co‐infection with H. pylori was common (18.2%), while NHPH mono‐infection was uncommon (3.4%), with most NHPH‐positive biopsies also positive for H. pylori (84.4%). Prevalence estimates of gastric NHPH in humans vary widely across geographic settings and across study designs and diagnostic approaches (Table 1). Earlier studies, often relying on histology with limited molecular confirmation, typically reported NHPH detection rates of 0.2%–6% [8]. However, more recent molecular studies demonstrated that prevalence can be substantially higher in select clinical populations and when broad PCR‐based detection is applied. For example, in well‐defined H. pylori ‐negative gastric disease cohorts in Belgium, NHPH was detected in approximately 28%–29% of cases [9], whereas routine biopsy workflows in the USA have reported lower rates of around 1%–3%, depending on the population and sampling context [22]. In addition, a recent PCR‐based study from Portugal reported H. bizzozeronii in 35.9% (14/54) of patients undergoing upper gastrointestinal endoscopy, with mixed infection with H. pylori observed in 22.2% [23]. The NHPH detection rate of 21.6% observed in the present cohort likely reflects the combined influence of local epidemiology and a sensitive PCR‐based strategy applied across a large endoscopy‐derived sample set. The prevalence and species distribution observed here differ from many earlier reports in which human gastric NHPH infections were described as relatively uncommon and frequently dominated by pig‐associated species, such as H. suis , rather than dog‐ and cat‐associated species [8, 12, 20, 24]. In the present cohort, H. bizzozeronii was considerably more frequent as compared to other recent studies (Table 1). This The predominance of H. bizzozeronii in the present cohort is biologically plausible because H. bizzozeronii is a well‐established gastric colonizer of dogs and has been repeatedly implicated in zoonotic transmission to humans [5, 24, 25, 26, 27, 28]. In Israel, where the dog population is estimated at approximately 600,000, human exposure to canine reservoirs is likely common, although this study did not directly assess individual exposure history [29]. The findings raise the possibility that H. bizzozeronii is under‐detected in routine histology‐driven workflows without species‐specific molecular screening for NHPH. Future studies incorporating standardized exposure histories (e.g., pet ownership, intensity of dog and cat contact, and occupational animal exposure) will be important to clarify whether this species predominance reflects zoonotic exposure patterns. NHPH prevalence, driven primarily by H. bizzozeronii , was higher in females. Although causal inference is not possible, differences in exposure patterns (e.g., pet ownership and intensity of contact with dogs and cats), host susceptibility and healthcare‐seeking behavior may all contribute to the observed female predominance. A marked seasonality signal for H. bizzozeronii was also observed, with the highest rates in autumn (29.7%), compared with spring (15.6%), summer (14.3%) and winter (19.9%) (p = 0.0002). H. pylori PCR detection similarly varied by season (83.0% in autumn vs. 72.3%–81.6% in other seasons, p = 0.007). It remains to be determined whether these patterns reflect true seasonal variation in exposure or transmission, differences in referral and sampling across seasons, or other operational factors. Future studies should aim to systematically capture season, exposure variables and key clinical confounders (e.g., recent antibiotics and acid suppression) to better define the drivers of NHPH infection. The strong tendency toward co‐infection in the current dataset is consistent with prior works indicating that NHPH is frequently detected alongside H. pylori rather than alone [21, 23]. Several mechanisms may account for this pattern. First, shared exposure pathways may contribute, as individuals with close contact with animal reservoirs (particularly dogs and cats) may be at increased risk of acquiring NHPH, while simultaneously being exposed to human‐associated H. pylori through intrafamilial transmission or environmental routes [3]. Second, chronic H. pylori ‐associated gastritis may modify the gastric microenvironment, potentially facilitating transient colonization or persistence of other Helicobacter species. Third, referral and sampling context may bias detection; as patients undergo endoscopy primarily due to suspected H. pylori infection, NHPH testing is disproportionately performed in a cohort enriched for H. pylori , increasing the apparent frequency of co‐detection. Collectively, these considerations complicate causal attribution of mucosal injury to NHPH alone in co‐infected patients. In the current cohort, there was no apparent difference in the severity of clinical symptoms and endoscopic findings among NHPH‐positive groups compared with H. pylori mono‐infected cases. Thus, although NHPH species have been linked to chronic gastritis [8], peptic ulcer disease [30], and, in selected reports, gastric MALT lymphoma [16, 31, 32, 33], the presented population‐level data do not support a distinctly more aggressive phenotype associated with co‐infection in this routine endoscopy‐derived setting. Clinically, NHPH detection may still be important in specific scenarios, particularly in cases of H. pylori ‐negative gastritis with suggestive histology or in gastric MALT lymphoma, where clarifying etiological factors can influence interpretation and subsequent management. In these contexts, diagnosis can be refined by using molecular testing as a complementary approach to routine histology, with the caveat that PCR identifies bacterial DNA but does not confirm active infection. Across PCR‐defined infection categories, the clearest histopathologic distinction was observed in the distribution of foveolar hyperplasia. Foveolar hyperplasia was less frequent in H. pylori ‐positive groups (co‐infection and H. pylori mono‐infection) and more frequent in NHPH‐only and PCR‐negative groups. A similar pattern was observed when restricting the analysis to H. bizzozeronii , with the highest proportion of foveolar hyperplasia measured in H. bizzozeronii mono‐infection samples. Several interpretations of this phenomenon should be considered. First, foveolar hyperplasia is widely regarded as a reactive epithelial change and may reflect the existence of noninfectious drivers such as chemical injury, bile reflux, or medication‐associated gastropathy [34, 35], which could be more prevalent among Helicobacter‐negative patients undergoing endoscopy. Second, in the absence of H. pylori , NHPH is more likely to represent the primary colonizing organism rather than a low‐abundance co‐detected species. This may increase the likelihood that any associated epithelial changes reflect the biological impact of NHPH itself, rather than being masked by concurrent H. pylori infection. However, given the relatively small size of the NHPH‐only group, these findings should be interpreted cautiously and viewed as hypothesis‐generating. Consistent with these histopathologic observations, no clear increase in symptom burden or endoscopic severity was observed across NHPH infection groups, either alone or in combination with H. pylori , compared with H. pylori mono‐infection. This finding is clinically relevant because it suggests that NHPH can be considered a co‐occurring finding rather than as a marker of a more aggressive phenotype. Moreover, several common endoscopic endpoints are strongly influenced by noninfectious factors, including NSAID exposure, bile reflux, and other causes of reactive gastropathy, which can obscure differences attributable to Helicobacter status in routine practice. Accordingly, the clinical utility of NHPH testing may be greatest in targeted scenarios, such as H. pylori ‐negative gastritis with suggestive histology or diagnostically unresolved cases, rather than as a broad severity marker. Taken together, these findings suggest that NHPH detection is not associated with increased endoscopic severity in this cohort. In contrast, H. pylori infection has been consistently linked to characteristic endoscopic patterns in prior studies [35], which may explain the limited contribution of NHPH status to the macroscopic findings observed here. Future studies are needed to determine whether NHPH is associated with cellular‐level changes that may not always translate into detectable tissue‐level or endoscopic findings in the short term but may have long‐term implications. This study had limitations that should be considered when interpreting the findings. The retrospective, single‐center design and inclusion of patients undergoing clinically indicated upper endoscopy introduce potential selection bias and limit generalizability beyond comparable endoscopy‐derived clinical populations. Although internal comparisons were performed across PCR‐defined infection categories, the absence of an asymptomatic control group precludes inference regarding prevalence in the general population. Important clinical and exposure variables were not uniformly available, including recent antibiotic therapy, proton pump inhibitor and NSAID use, and detailed zoonotic exposure data, all of which may influence both Helicobacter detection and clinicopathologic outcomes. PCR performed on FFPE‐derived tissue identifies bacterial DNA but cannot independently distinguish active infection from low‐bacterial‐level carriage or residual DNA, nor does it establish tissue localization. In addition, species attribution was not systematically confirmed across all positive samples using independent confirmatory methods. Several NHPH species were infrequent and the NHPH‐only subgroup was relatively small, limiting statistical power for species‐specific inference. Despite these limitations, the large cohort size, systematic multi‐target PCR screening and its integration with clinical, endoscopic, and histopathologic data, provided rigorous characterization of NHPH patterns within a routine clinical endoscopy setting and define a clear framework for prospective validation. Conclusion In this large endoscopy‐derived sample set, NHPH species were detected by multi‐target PCR in 21.6% of gastric biopsies, with H. bizzozeronii occurring in the majority of samples, most often alongside H. pylori . NHPH prevalence varied by gender and demonstrated a pronounced seasonal peak, suggesting a nonrandom epidemiologic patterning that should be tested in independent cohorts incorporating standardized exposure and medication data. For the clinical and endoscopic outcomes evaluated, NHPH detection—either alone or with H. pylori —was not associated with a clearly more severe symptom burden or macroscopic endoscopic phenotype compared with H. pylori mono‐infection, indicating that co‐detection does not necessarily imply increased disease severity in routine practice. In contrast, the higher frequency of foveolar hyperplasia in NHPH‐only infections underscores the value of molecular testing for refining infection classification and motivates focused tissue‐level and mechanistic studies. Together, these findings provide robust estimates of NHPH prevalence and species distribution within a routine clinical biopsy setting and define priorities for prospective validation of exposure determinants, seasonality and clinical contexts in which NHPH testing can add diagnostic value. Author Contributions Conceptualization, D.V., M.A., Y.M., and A.P.; Methodology, D.V., M.A., M.N., H.R., Y.M., and A.P.; Investigation, D.V., M.A., M.N., and H.R.; Data curation, D.V., M.A., M.N., and H.R.; Formal analysis, D.V. and M.A.; Validation, D.V., M.A., Y.M., and A.P.; Visualization, D.V., M.A., Y.M., and A.P.; Project administration, M.A.; Supervision, M.A., Y.M., and A.P.; Writing – original draft, D.V., M.A., Y.M., and A.P.; Writing – review and editing, D.V., M.A., Y.M., and A.P. All authors have read and agreed to the published version of the manuscript. Acknowledgments The authors would like to express their sincere appreciation to the staff of the Clinical Microbiology Laboratory and the Pathology Institute at Tzafon Medical Center for their invaluable training, technical assistance, and troubleshooting support. TABLE A1PCR primers used for species‐specific PCR detection.Species taxonGenePrimer sequenceProduct size (bp)Running instructions H. suis UreAB FW (5′‐AAA ACA MAG GCG ATC GCC CTG TA‐3′) a 1503′ 95°C 40 × (1′ 94°C—1′ 59°C—1′ 72°C) 5′ 72°CRV (5′‐TTT CTT CGC CAG GTT CAA AGC G‐3′) H. bizzozeronii UreAB FW (5′‐CGC TTT GAA CCC GGT GAG AAA A‐3′)1723′ 94°C 35 × (30″ 94°C—30″ 58°C—1′ 72°C) 10′ 72°CRV (5′‐TAT CGC AAC CGC AAT TCA CAA CA‐3′) H. felis UreAB FW (5′‐GCT GGT GGC ATC GAT ACG CAT‐3′)1544′ 95°C 45 × (30″ 94°C—30″ 60°C—1′ 72°C) 10′ 72°CRV (5′‐TTT TTA GAT TAG CGC GTC CGG GA‐3′) H. salomonis UreAB FW (5′‐CTC TTA TGA GTT GGA CTT GGT GCT CAC CAA T‐3′)914′ 95°C 45 × (30″ 94°C—30″ 61°C—1′ 72°C) 10′ 72°CRV (5′‐TTT GCC ATC TTT AAT TCC AAT GTC GGC‐3′) H. heilmannii s.s. IceA FW (5′‐GTT TCC AAC CAA AAG ACT CA‐3′)1353′ 94°C 35 × (30″ 94°C—30″ 55°C—1′ 72°C) 10′ 72°CRV (5′‐ATT GCC TAG AGG TTG TGT TG‐3′) H. ailurogastricus LpsA FW (5′‐CTT GAG TAC GGC GAT GTC AAT‐3′)1363′ 94°C 35 × (30″ 94°C—30″ 55°C—1′ 72°C) 10′ 72°CRV (5′‐GGG GAA AAA TGT GCT TGA AGT‐3′)RV (5′‐GGG TTT TAC CGC CAC CGA ATT TAA‐3′) H. pylori glmM (UreC)FW (5′‐TTATCGGTAAAGACACCAGAAA‐3′)1443′ 94°C 35 × (30″ 94°C—30″ 57°C—1′ 72°C) 10′ 72°CRV (5′‐ATCACAGCGCATGTCTTC‐3′) a M = A or C. PCR primers used for species‐specific PCR detection. M = A or C. TABLE A2Prevalence of PCR‐detected NHPH species by gender.OrganismMale n/N, % (95% CI)Female n/N, % (95% CI) p Any NHPH69/380, 18.2% (14.6–22.3)110/450, 24.4% (20.7–28.6) 0.0282 H. bizzozeronii 63/380, 16.6% (13.2–20.6)104/450, 23.1% (19.5–27.2) 0.0193 H. heilmannii 2/380, 0.5% (0.1–1.9)5/450, 1.1% (0.5–2.6)0.4628 H. felis 3/380, 0.8% (0.3–2.3)3/450, 0.7% (0.2–1.9)1.0000 H. ailurogastricus 1/380, 0.3% (0.0–1.5)2/450, 0.4% (0.1–1.6)1.0000 H. suis 0/380, 0.0% (0.0–1.0)0/450, 0.0% (0.0–0.8)— H. salomonis 0/380, 0.0% (0.0–1.0)0/450, 0.0% (0.0–0.8)— Note: Bold values are statistically significant p values. Prevalence of PCR‐detected NHPH species by gender. Note: Bold values are statistically significant p values. TABLE A3Prevalence of PCR‐detected NHPH species by age group.Organism< 18 years n/N, % (95% CI)18–40 years n/N, % (95% CI)41–60 years n/N, % (95% CI)≥ 61 years n/N, % (95% CI) p Any NHPH58/214, 27.1% (21.6–33.4)32/161, 19.9% (14.4–26.7)43/218, 19.7% (15.0–25.5)46/237, 19.4% (14.9–24.9)0.1551 H. bizzozeronii 56/214, 26.2% (20.7–32.4)29/161, 18.0% (12.8–24.7)42/218, 19.3% (14.6–25.0)40/237, 16.9% (12.6–22.2)0.0730 H. heilmannii 1/214, 0.5% (0.1–2.6)1/161, 0.6% (0.1–3.4)1/218, 0.5% (0.1–2.6)4/237, 1.7% (0.7–4.3)0.4132 H. felis 2/214, 0.9% (0.3–3.3)2/161, 1.2% (0.3–4.4)0/218, 0.0% (0.0–1.7)2/237, 0.8% (0.2–3.0)0.4984 H. ailurogastricus 0/214, 0.0% (0.0–1.8)0/161, 0.0% (0.0–2.3)1/218, 0.5% (0.1–2.6)2/237, 0.8% (0.2–3.0)0.3995 H. suis 0/214, 0.0% (0.0–1.8)0/161, 0.0% (0.0–2.3)0/218, 0.0% (0.0–1.7)0/237, 0.0% (0.0–1.6)— H. salomonis 0/214, 0.0% (0.0–1.8)0/161, 0.0% (0.0–2.3)0/218, 0.0% (0.0–1.7)0/237, 0.0% (0.0–1.6)— Prevalence of PCR‐detected NHPH species by age group. TABLE A4PCR‐detected NHPH species by nationality.OrganismJewish n/N, % (95% CI)Arab n/N, % (95% CI)Other n/N, % (95% CI) p Any NHPH142/655, 21.7% (18.7–25.0)35/166, 21.1% (15.6–27.9)2/9, 22.2% (6.3–54.7)0.9851 H. bizzozeronii 132/655, 20.2% (17.3–23.4)34/166, 20.5% (15.0–27.3)1/9, 11.1% (2.0–43.5)0.7912 H. heilmannii 6/655, 0.8% (0.4–2)1/166, 0.6% (0.1–3.3)0/9, 0.0% (0.0–29.9)0.8900 H. felis 5/655, 0.8% (0.3–1.8)0/166, 0.0% (0.0–2.3)1/9, 11.1% (2.0–43.5)0.0006 H. ailurogastricus 3/655, 0.5% (0.2–1.3)0/166, 0.0% (0.0–2.3)0/9, 0.0% (0.0–29.9)0.6688 H. suis 0/655, 0.0% (0.0–0.6)0/166, 0.0% (0.0–2.3)0/9, 0.0% (0.0–29.9)— H. salomonis 0/655, 0.0% (0.0–0.6)0/166, 0.0% (0.0–2.3)0/9, 0.0% (0.0–29.9)— PCR‐detected NHPH species by nationality. TABLE A5PCR‐detected NHPH species by residence type.OrganismCity n/N, % (95% CI)Village n/N, % (95% CI)Local council n/N, % (95% CI) p Any NHPH91/478, 19.0% (15.7–22.9)58/244, 23.8% (18.9–29.4)30/108, 27.8% (20.2–36.8)0.0833 H. bizzozeronii 85/478, 17.8% (14.6–21.6)54/244, 22.1% (17.4–27.8)28/108, 25.9% (18.5–35.0)0.0948 H. heilmannii 2/478, 0.4% (0.1–1.5)3/244, 1.2% (0.4–3.6)2/108, 1.9% (0.5–6.4)0.6223 H. felis 5/478, 1.0% (0.4–2.4)1/244, 0.4% (0.0–2.8)0/108, 0.0% (0.0–3.4)0.5552 H. ailurogastricus 2/478, 0.4% (0.1–1.5)0/244, 0.0% (0.0–1.5)0/108, 0.0% (0.0–3.4)0.6550 H. suis 0/478, 0.0% (0.0–0.8)0/244, 0.0% (0.0–1.5)0/108, 0.0% (0.0–3.4)— H. salomonis 0/478, 0.0% (0.0–0.8)0/244, 0.0% (0.0–1.5)0/108, 0.0% (0.0–3.4)— PCR‐detected NHPH species by residence type. TABLE A6PCR‐detected NHPH species by biopsy site.OrganismAntrum n/N, % (95% CI)Corpus n/N, % (95% CI)Antrum + Corpus n/N, % (95% CI) p Any NHPH97/492, 19.7% (16.4–23.5)44/167, 26.3% (20.1–33.6)36/165, 21.8% (16.1–28.8)0.3003 H. bizzozeronii 93/492, 18.9% (15.7–22.6)39/167, 23.4% (17.5–30.5)34/165, 20.6% (15.0–27.7)0.2293 H. heilmannii 5/492, 1.0% (0.4–2.4)2/167, 1.2% (0.3–4.2)0/165, 0.0% (0.0–2.3)0.7544 H. felis 3/492, 0.6% (0.2–1.8)2/167, 1.2% (0.3–4.2)1/165, 0.6% (0.1–3.4)0.9316 H. ailurogastricus 0/492, 0.0% (0.0–0.8)1/167, 0.6% (0.1–3.3)1/165, 0.6% (0.1–3.4)0.9888 H. suis 0/492, 0.0% (0.0–0.8)0/167, 0.0% (0.0–2.3)0/165, 0.0% (0.0–2.3)— H. salomonis 0/492, 0.0% (0.0–0.8)0/167, 0.0% (0.0–2.3)0/165, 0.0% (0.0–2.3)— PCR‐detected NHPH species by biopsy site. TABLE A7PCR‐detected NHPH species by season.OrganismAutumn n/N, % (95% CI)Spring n/N, % (95% CI)Summer n/N, % (95% CI)Winter n/N, % (95% CI) p Any NHPH73/229, 31.9% (26.2–38.2)38/224, 17.0% (12.6–22.4)30/196, 15.3% (10.9–21.0)38/181, 21.0% (15.7–27.5) < 0.0001 H. bizzozeronii 68/229, 29.7% (24.2–35.9)35/224, 15.6% (11.5–21.0)28/196, 14.3% (10.1–19.9)36/181, 19.9% (14.7–26.3) 0.0002 H. heilmannii 2/229, 0.9% (0.2–3.1)1/224, 0.4% (0.1–2.5)1/196, 0.5% (0.1–2.8)3/181, 1.7% (0.6–4.8)0.5481 H. felis 2/229, 0.9% (0.2–3.1)1/224, 0.4% (0.1–2.5)2/196, 1.0% (0.3–3.6)1/181, 0.6% (0.1–3.1)0.8905 H. ailurogastricus 2/229, 0.9% (0.2–3.1)0/224, 0.0% (0.0–1.7)0/196, 0.0% (0.0–1.9)0/181, 0.0% (0.0–2.1)0.3796 H. suis 0/229, 0.0% (0.0–1.6)0/224, 0.0% (0.0–1.7)0/196, 0.0% (0.0–1.9)0/181, 0.0% (0.0–2.1)— H. salomonis 0/229, 0.0% (0.0–1.6)0/224, 0.0% (0.0–1.7)0/196, 0.0% (0.0–1.9)0/181, 0.0% (0.0–2.1)— Note: Percentages in Tables A2, A3, A4, A5, A6, A7 were calculated within each subgroup. Confidence intervals (95% CI) were calculated using the Wilson method. “Any NHPH” indicates detection of at least one non‐ H. pylori Helicobacter species; totals may exceed due to co‐detection of multiple NHPH species in individual samples. Analyses were conducted using available PCR data only. Bold values are statistically significant p values. PCR‐detected NHPH species by season. Note: Percentages in Tables A2, A3, A4, A5, A6, A7 were calculated within each subgroup. Confidence intervals (95% CI) were calculated using the Wilson method. “Any NHPH” indicates detection of at least one non‐ H. pylori Helicobacter species; totals may exceed due to co‐detection of multiple NHPH species in individual samples. Analyses were conducted using available PCR data only. Bold values are statistically significant p values. TABLE A8Clinical, endoscopic (EGD), and pathological findings by any NHPH infection group.VariableAny NHPH—infection groupsCo‐infection (Hp+ & NHPH+) n/N (%)Hp only (Hp+ & NHPH−) n/N (%)NHPH only (Hp− & NHPH+) n/N (%)PCR negative (Hp− & NHPH−) n/N (%) p Clinical findingsAbdominal pain75/151 (49.7%)276/492 (56.1%)15/28 (53.6%)82/159 (51.6%)0.4954Vomiting14/151 (9.3%)39/492 (7.9%)3/28 (10.7%)17/159 (10.7%)0.7181GERD/heartburn20/151 (13.2%)52/492 (10.6%)3/28 (10.7%)18/159 (11.3%)0.8398Weight loss7/151 (4.6%)19/492 (3.9%)0/28 (0.0%)7/159 (4.4%)0.6999Iron deficiency anemia8/151 (5.3%)50/492 (10.2%)2/28 (7.1%)15/159 (9.4%)0.3235Melena12/151 (7.9%)30/492 (6.1%)0/28 (0.0%)10/159 (6.3%)0.4536Endoscopic findings (EGD)Any gastric peptic lesion21/151 (13.9%)76/492 (15.4%)3/28 (10.7%)43/159 (27.0%) 0.0031 Gastric erosions20/151 (13.2%)68/492 (13.8%)3/28 (10.7%)36/159 (22.6%) 0.0386 Gastric ulcers1/151 (0.7%)13/492 (2.6%)0/28 (0.0%)11/159 (6.9%) 0.0065 Any duodenal peptic lesion14/151 (9.3%)62/492 (12.6%)5/28 (17.9%)24/159 (15.1%)0.3753Duodenal erosions11/151 (7.3%)49/492 (10.0%)4/28 (14.3%)19/159 (11.9%)0.4788Duodenal ulcers3/151 (2.0%)18/492 (3.7%)1/28 (3.6%)6/159 (3.8%)0.7783Duodenitis26/151 (17.2%)103/492 (20.9%)5/28 (17.9%)35/159 (22.0%)0.7067Spotty redness15/151 (9.9%)23/492 (4.7%)2/28 (7.1%)10/159 (6.3%)0.1249Crack‐like mucosa0/151 (0.0%)3/492 (0.6%)0/28 (0.0%)0/159 (0.0%)0.5583Pathological findingsFoveolar hyperplasia15/151 (9.9%)47/492 (9.6%)8/28 (28.6%)38/159 (23.9%) < 0.0001 Dysplasia0/151 (0.0%)0/492 (0.0%)0/28 (0.0%)1/159 (0.6%)0.2381Any cancer (histopath)1/151 (0.7%)1/492 (0.2%)0/28 (0.0%)1/159 (0.6%)0.7677 Note: Bold values are statistically significant p values.Abbreviations: Hp, H. pylori ; NHPH, non‐H. pylori Helicobacter. Clinical, endoscopic (EGD), and pathological findings by any NHPH infection group. Note: Bold values are statistically significant p values. Abbreviations: Hp, H. pylori ; NHPH, non‐H. pylori Helicobacter. TABLE A9Clinical, endoscopic (EGD), and pathological findings by H. bizzozeronii infection group.Variable H. bizzozeronii —infection groupsCo‐infection (Hp+ & biz+) n/N (%)Hp only (Hp+ & biz−) n/N (%)biz only (Hp− & biz+) n/N (%)PCR negative (Hp− & biz−) n/N (%) p Clinical findingsAbdominal pain72/140 (51.4%)279/503 (55.5%)14/27 (51.9%)83/160 (51.9%)0.7652Vomiting13/140 (9.3%)40/503 (8.0%)3/27 (11.1%)17/160 (10.6%)0.7206GERD/heartburn20/140 (14.3%)52/503 (10.3%)3/27 (11.1%)18/160 (11.2%)0.6334Weight loss6/140 (4.3%)20/503 (4.0%)0/27 (0.0%)7/160 (4.4%)0.7482Iron deficiency anemia6/140 (4.3%)52/503 (10.3%)2/27 (7.4%)15/160 (9.4%)0.1725Melena9/140 (6.4%)33/502 (6.6%)0/27 (0.0%)10/160 (6.2%)0.5955Endoscopic findings (EGD)Any gastric peptic lesion18/140 (12.9%)79/503 (15.7%)3/27 (11.1%)43/160 (26.9%) 0.0031 Gastric erosions18/140 (12.9%)70/503 (13.9%)3/27 (11.1%)36/160 (22.5%) 0.0430 Gastric ulcers0/140 (0.0%)14/503 (2.8%)0/27 (0.0%)11/160 (6.9%) 0.0038 Any duodenal peptic lesion12/140 (8.6%)64/503 (12.7%)5/27 (18.5%)24/160 (15.0%)0.2896Duodenal erosions10/140 (7.1%)50/503 (9.9%)4/27 (14.8%)19/160 (11.9%)0.4588Duodenal ulcers2/140 (1.4%)19/503 (3.8%)1/27 (3.7%)6/160 (3.8%)0.5818Duodenitis22/140 (15.7%)107/503 (21.3%)5/27 (18.5%)35/160 (21.9%)0.4928Spotty redness15/140 (10.7%)23/503 (4.6%)2/27 (7.4%)10/160 (6.2%)0.0597Crack‐like mucosa0/140 (0.0%)3/503 (0.6%)0/27 (0.0%)0/160 (0.0%)0.5813Pathological findingsFoveolar hyperplasia13/140 (9.3%)49/503 (9.7%)8/27 (29.6%)38/160 (23.8%) < 0.0001 Dysplasia0/140 (0.0%)0/503 (0.0%)0/27 (0.0%)1/160 (0.6%)0.2414Any cancer (histopath)1/140 (0.7%)1/503 (0.2%)0/27 (0.0%)1/160 (0.6%)0.7387 Note: Bold values are statistically significant p values.Abbreviations: Hp, H. pylori; biz, H. bizzozeronii. Clinical, endoscopic (EGD), and pathological findings by H. bizzozeronii infection group. Note: Bold values are statistically significant p values. Abbreviations: Hp, H. pylori; biz, H. bizzozeronii. Vizenblit D., Azrad M., Nashashibi M., Roshrosh H., Maman Y., and Peretz A., “Beyond Helicobacter pylori: Prevalence, Coinfection, and Clinicopathologic Patterns of Non‐Helicobacter pylori Helicobacter (NHPH) in Human Gastric Biopsies,” Helicobacter 31, no. 5 (2026): e70165, 10.1111/hel.70165. Maya Azrad, Munir Nashashibi, Halim Roshrosh, and Avi Peretz: Affiliated with Azriely Faculty of Medicine, Bar Ilan University, Safed, Israel Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.